229 related articles for article (PubMed ID: 35468838)
1. Comprehensive analysis of prognostic value and immune infiltration of CXC chemokines in pancreatic cancer.
Jing Y; Wang F; Zhang K; Chen Z
BMC Med Genomics; 2022 Apr; 15(1):96. PubMed ID: 35468838
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Targets and Prognostic Biomarkers Among CXC Chemokines in Pancreatic Ductal Adenocarcinoma Microenvironment.
Yin Z; Chen S
Pancreas; 2022 Oct; 51(9):1235-1247. PubMed ID: 37078951
[TBL] [Abstract][Full Text] [Related]
3. Expression and clinical significance of CXC chemokines in the glioblastoma microenvironment.
Li C; Deng H; Zhou Y; Ye Y; Zhao S; Liang S; Cai S; Lin J; Tang Y; Wu Y
Life Sci; 2020 Nov; 261():118486. PubMed ID: 32976881
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Biomarkers and Immunotherapeutic Targets Among CXC Chemokines in Pancreatic Adenocarcinoma.
Huang J; Chen Z; Ding C; Lin S; Wan D; Ren K
Front Oncol; 2021; 11():711402. PubMed ID: 34497764
[TBL] [Abstract][Full Text] [Related]
5. A novel prognostic signature of chemokines for survival and immune infiltration in kidney renal clear cell carcinoma.
Weng J; Huang Z; Li Q; Huang Y; Chen S
Int J Med Sci; 2023; 20(8):1046-1059. PubMed ID: 37484803
[No Abstract] [Full Text] [Related]
6. Exploration of prognostic biomarkers and therapeutic targets in the microenvironment of bladder cancer based on CXC chemokines.
Sun X; Chen Q; Zhang L; Chen J; Zhang X
Math Biosci Eng; 2021 Jul; 18(5):6262-6287. PubMed ID: 34517533
[TBL] [Abstract][Full Text] [Related]
7. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
8. Identification of Key Prognostic Biomarker and Its Correlation with Immune Infiltrates in Pancreatic Ductal Adenocarcinoma.
Luan H; Zhang C; Zhang T; He Y; Su Y; Zhou L
Dis Markers; 2020; 2020():8825997. PubMed ID: 32934754
[TBL] [Abstract][Full Text] [Related]
9. Molecular profiling of stroma highlights stratifin as a novel biomarker of poor prognosis in pancreatic ductal adenocarcinoma.
Robin F; Angenard G; Cano L; Courtin-Tanguy L; Gaignard E; Khene ZE; Bergeat D; Clément B; Boudjema K; Coulouarn C; Sulpice L
Br J Cancer; 2020 Jul; 123(1):72-80. PubMed ID: 32376891
[TBL] [Abstract][Full Text] [Related]
10. The coagulation-related genes for prognosis and tumor microenvironment in pancreatic ductal adenocarcinoma.
Wang D; Cui SP; Chen Q; Ren ZY; Lyu SC; Zhao X; Lang R
BMC Cancer; 2023 Jun; 23(1):601. PubMed ID: 37386391
[TBL] [Abstract][Full Text] [Related]
11. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
12. Expression and potential function of the CXC chemokine CXCL16 in pancreatic ductal adenocarcinoma.
Wente MN; Gaida MM; Mayer C; Michalski CW; Haag N; Giese T; Felix K; Bergmann F; Giese NA; Friess H
Int J Oncol; 2008 Aug; 33(2):297-308. PubMed ID: 18636150
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism.
Sun X; He X; Zhang Y; Hosaka K; Andersson P; Wu J; Wu J; Jing X; Du Q; Hui X; Ding B; Guo Z; Hong A; Liu X; Wang Y; Ji Q; Beyaert R; Yang Y; Li Q; Cao Y
Gut; 2022 Jan; 71(1):129-147. PubMed ID: 33568427
[TBL] [Abstract][Full Text] [Related]
14. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma.
Ijichi H; Chytil A; Gorska AE; Aakre ME; Bierie B; Tada M; Mohri D; Miyabayashi K; Asaoka Y; Maeda S; Ikenoue T; Tateishi K; Wright CV; Koike K; Omata M; Moses HL
J Clin Invest; 2011 Oct; 121(10):4106-17. PubMed ID: 21926469
[TBL] [Abstract][Full Text] [Related]
15. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of the prognosis and immune infiltration for CXC chemokines in colorectal cancer.
Yang X; Wei Y; Sheng F; Xu Y; Liu J; Gao L; Yang J; Sun X; Huang J; Guo Q
Aging (Albany NY); 2021 Jul; 13(13):17548-17567. PubMed ID: 34233297
[TBL] [Abstract][Full Text] [Related]
17. Exploration of potential therapeutic and prognostic value of CXC chemokines in cervical squamous cell carcinoma and endocervical adenocarcinoma based on bioinformatics analysis.
Wu C; Ma C; Yuan J; Zhou P
Math Biosci Eng; 2021 Sep; 18(6):8201-8222. PubMed ID: 34814296
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Analysis of Expression, Prognostic Value, and Immune Infiltration for Ubiquitination-Related FBXOs in Pancreatic Ductal Adenocarcinoma.
Zhang Y; Liu Q; Cui M; Wang M; Hua S; Gao J; Liao Q
Front Immunol; 2021; 12():774435. PubMed ID: 35046938
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein E is a prognostic factor for pancreatic cancer and associates with immune infiltration.
Wu B; Yang X; Chen F; Song Z; Ding X; Wang X
Cytokine; 2024 Jul; 179():156628. PubMed ID: 38704962
[TBL] [Abstract][Full Text] [Related]
20. Identification of therapeutic targets and prognostic biomarkers among CXC chemokines in hepatocellular carcinoma microenvironment.
Yin Z; Ma T; Chen S; Yu M
Cancer Biomark; 2023; 36(3):231-250. PubMed ID: 36938723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
